Amneal Pharmaceuticals, Inc. is a U.S.-domiciled publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals was founded in 2002 by brothers Chirag and Chintu Patel. The company manufactured its first Rx product in 2005 and received its first ANDA approval in 2006.

Amneal to Participate at Upcoming Investor Conferences

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review

Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinsons Disease

Amneal Pharmaceuticals Third Quarter 2022 Earnings: Misses Expectations

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates

Amneal Reports Third Quarter 2022 Financial Results

Select Medical (SEM) Q3 Earnings Miss Estimates

Amneal Receives FDA Approval for Leuprolide Acetate Injection

Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory

Institutional investors own a significant stake of 42% in Amneal Pharmaceuticals, Inc. (NYSE:AMRX)

Implied Volatility Surging for Amneal Pharmaceuticals (AMRX) Stock Options

Amneal to Report Third Quarter 2022 Results on November 4, 2022

Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States

10 Best 52-Week Low Small-Cap Stocks to Buy Now

Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer  Specialty

Amneal Seeks FDA Approval For Its Parkinson's Candidate

Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinsons Disease

Top Streaming News